Johnson & Johnson Secures U.S. Food and Drug Administration Approval for TECNIS PureSee Intraocular Lens, Expanding Vision Care Options for U.S. Cataract Patients Johnson & Johnson announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth…
Eli Lilly and Company Issues Open Letter Warning About Potential Patient Safety Risks of Tirzepatide Compounded with Vitamin B12 Lilly is issuing a public warning about potential safety risks associated with compounded tirzepatide mixed with vitamin B12. As part of…
GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications GoodRx the leading platform for prescription savings in the U.S., announced a new collaboration with Viatris, a global healthcare company, to make 17 of its established…
Planet DDS 2026 Dental Outlook Shows More New Patients, Fewer No-Shows Across the Industry Planet DDS, a leading provider of cloud-based, enterprise-grade dental software solutions, announced the release of its 2026 Dental Industry Outlook, an annual benchmark report designed to help…
GeneDx Study Shows Significant Healthcare Cost Savings and Improved Outcomes for Children After Genomic Testing A new real-world data study presented by GeneDx has revealed that genomic testing can dramatically reduce healthcare costs and improve clinical outcomes for children with…
InterSystems Appoints Tim Ferris as Vice President of Healthcare Practice InterSystems, a global data technology company that supports more than one billion health records worldwide, has announced the appointment of Tim Ferris as Vice President of its Healthcare Practice. The…
C2N Diagnostics Enters South Korean Market Through Partnership with BeauBrain Healthcare to Offer Precivity™ Portfolio of Blood Tests for Alzheimer’s Diagnosis Specialty diagnostics company C2N Diagnostics has announced a strategic partnership with South Korea–based healthcare firm BeauBrain Healthcare to introduce…
United Therapeutics Corporation Shares TETON-2 Phase 3 Trial Findings in The New England Journal of Medicine United Therapeutics Corporation announced that the complete findings from its Phase 3 TETON-2 clinical trial evaluating nebulized Tyvaso® (treprostinil) inhalation solution for the treatment…
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program Precision BioSciences, Inc. a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received…
Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with…